Evicenter
MarkdownMedical informationP&T meetings
Palazestrant (OP-1250)

Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

Manufacturer
Olema Oncology
Last updated
256 sources

Clinical evidence

OP-1250-002

30 evidence topics · 6 sources

Objective
Location and study date
Registry dates and enrollment
ItemValue
Study start (actual)“2021-12-10”
Primary completion (estimated)“2026-03”
Enrollment (actual)“60”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using dose-limiting toxicities as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants by palazestrant dose, September 2023 data cutoff
Description of analysis sets
Results
Participant disposition
Treatment status and reasons for discontinuation, September 2023 data cutoff
StatusTotal (N=46), n (%)
Treatment ongoing“22 (48)”
Treatment discontinued“24 (52)”
Discontinued for disease progression“18 (39)”
Discontinued for physician decision“3 (7)”
Discontinued for patient decision“2 (4)”
Discontinued for adverse event“1 (2)”
Baseline characteristics
Baseline demographics and disease characteristics, September 2023 data cutoff
CharacteristicTotal (N=46), n (%)
Median age, years (range)“63.5 (30–77)”
Female sex“45 (98)”
Premenopausal“4 (9)”
ECOG performance status 0“31 (67)”
ECOG performance status 1“15 (33)”
Measurable disease“36 (78)”
Visceral disease“20 (44)”
One prior line of therapy for advanced disease“34 (74)”
One prior line of endocrine therapy for advanced disease“40 (87)”
Prior CDK4/6 inhibitor for advanced disease“33 (72)”
Prior aromatase inhibitor for advanced disease“35 (76)”
Prior fulvestrant for advanced disease“5 (11)”
Prior chemotherapy for advanced disease“10 (22)”
ESR1 mutation at baseline (ctDNA)“16/37 (43)”
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Treatment-emergent adverse events in at least 20% of participants, total population (N=46), n (%)
EventAll gradesGrade 3Grade 4
Neutropenia (combined term)“40 (87)”“28 (61)”“5 (11)”
Nausea“26 (57)”“0”“0”
Vomiting“17 (37)”“0”“0”
Anemia“12 (26)”“1 (2)”“0”
Diarrhea“11 (24)”“0”“0”
Constipation“10 (22)”“1 (2)”“0”
Fatigue“10 (22)”“1 (2)”“0”
Thrombocytopenia“10 (22)”“0”“0”
Study limitations
Summary

OP-1250-002 is an open-label phase 1b dose-escalation and dose-expansion study. Eligibility allowed zero or one prior endocrine therapy with or without a CDK4/6 inhibitor for advanced disease, which admits participants outside previously treated disease; 33 of 46 participants (72%) had received a prior CDK4/6 inhibitor. The CBR is based on 26 evaluable participants overall and 10 with ESR1 mutations, and circulating tumor DNA for ESR1 testing was available for 37 participants. The reported results have a data cutoff of September 15, 2023, at which 22 participants (48%) remained on treatment and the data were described as maturing. The registry lists an actual enrollment of 60 participants, whereas the reported analysis includes 46.